The article discusses the dysregulation of the cellular mesenchymal-epithelial transition (c-MET) factor of biotechnology company Genentech. Topics discussed include the suspension of the phase three of the firm's non small—cell lung cancer (NSCLC) study, the therapeutic benefits of onartuzumab cancer drug, and the potential benefit of combining onartuzumab with endothelial growth factor receptor (EGFR) inhibitor Tarceva (erlotinib).